Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis

Bone

Volumn 67, Issue , 2014, Pages 246-256

  Eriksen, Erik F ^a   Keaveny, Tony M ^b   Gallagher, Eileen R ^c   Krege, John H ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SYNEOS HEALTH   (United States)

^d Lilly Corporate Center   (United States)

Author keywords

BMD; Femur; Finite element analysis; Hip; Histomorphometry; Teriparatide

Indexed keywords

ALENDRONIC ACID; CALCIUM; DENOSUMAB; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; BONE MASS; BONE SCINTISCANNING; BONE STRENGTH; BONE STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL THICKNESS (BONE); CORTICOSTEROID INDUCED OSTEOPOROSIS; DATA ANALYSIS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FINITE ELEMENT ANALYSIS; HIP; HIP FRACTURE; HUMAN; MORPHOMETRICS; OSSIFICATION; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; DRUG EFFECTS; METABOLISM;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; HIP JOINT; HUMANS; OSTEOPOROSIS; TERIPARATIDE;

EID: 84905246905     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.07.014     Document Type: Review

References (103)

1. U.S. Department of Health and Human Services Bone health and osteoporosis. A report of the Surgeon General 2004, U.S. Department of Health and Human Services, Office of the Surgeon General, [http://www.surgeongeneral.gov/library/reports/bonehealth/full_report_pdf. Published 2004. Accessed December 13, 2013].
2. Osteoporosis Foundation Facts Statistics International Osteoporosis Foundation website [Accessed December 13, 2013]. http://www.iofbonehealth.org/facts-and-statistics/index.html11-5-2013.
3. Kanis J.A., Oden A., McCloskey E.V., Johansson H., Wahl D.A., Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012, 23:2239-2256.
4. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475.
5. Bentler S.E., Liu L., Obrizan M., Cook E.A., Wright K.B., Geweke J.F., et al. The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epidemiol 2009, 170:1290-1299.
6. Panula J., Pihlajamaki H., Mattila V.M., Jaatinen P., Vahlberg T., Aarnio P., et al. Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. BMC Musculoskelet Disord 2011, 12:105.
7. Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009, 301:513-521.
8. Cauley J.A. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci 2013, 68:1243-1251.
9. FORTEO [full prescribing information] Eli Lilly and Company, Indianapolis, IN; March 2012 [Accessed December 13, 2013]. http://pi.lilly.com/us/foreo-pi.pfd.
10. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
11. Dempster D.W., Zhou H., Recker R.R., Brown J.P., Bolognese M.A., Recknor C.P., et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab 2012, 97:2799-2808.
12. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
13. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253.
14. Ma Y.A., Marin M., Stepan J., Ish-Shalom S., Möricke R., Hawkins F., et al. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis. Bone 2011, 48:972-978.
15. McClung M.R., San M.J., Miller P.D., Civitelli R., Bandeira F., Omizo M., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. [Erratum appears in Arch Intern Med. 2005 Oct 10;165(18):2120]. Arch Intern Med 2005, 165:1762-1768.
16. Recker R.R., Marin F., Ish-Shalom S., Moricke R., Hawkins F., Kapetanos G., et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009, 24:1358-1368.
17. Stepan J.J., Burr D.B., Li J., Ma Y.L., Petto H., Sipos A., et al. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 2010, 21:2027-2036.
18. Ma Y.L., Zeng Q., Donley D.W., Ste-Marie L.G., Gallagher J.C., Dalsky G.P., et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:855-864.
19. Misof B.M., Paschalis E.P., Blouin S., Fratzl-Zelman N., Klaushofer K., Roschger P. Effects of 1year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res 2010, 25:2297-2303.
20. Paschalis E.P., Glass E.V., Donley D.W., Eriksen E.F. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. J Clin Endocrinol Metab 2005, 90:4644-4649.
21. Eriksen E.F., Robins D.A. Teriparatide: a bone formation treatment for osteoporosis. Drugs Today (Barc) 2004, 40:935-948.
22. Lindsay R., Cosman F., Zhou H., Bostrom M.P., Shen V.W., Cruz J.D., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006, 21:366-373.
23. Riggs B.L., Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005, 20:177-184.
24. Dobnig H., Stepan J.J., Burr D.B., Li J., Michalska D., Sipos A., et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 2009, 24:1998-2006.
25. Ma Y.L., Zeng Q.Q., Chiang A.Y., Burr D., Li J., Dobnig H., et al. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 2014, 59:139-147.
26. Moore A.E., Blake G.M., Taylor K.A., Rana A.E., Wong M., Chen P., et al. Assessment of regional changes in skeletal metabolism following 3 and 18months of teriparatide treatment. J Bone Miner Res 2010, 25:960-967.
27. Frost M.L., Siddique M., Blake G.M., Moore A.E., Schleyer P.J., Dunn J.T., et al. Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. J Bone Miner Res 2011, 26:1002-1011.
28. 18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: a prospective, randomized, controlled clinical study. J Bone Miner Res 2013, 28:1337-1347.
29. National Osteoporosis Foundation: clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. http://nof.org/files.nof/public/content/resource/913/files/580.pdf. Created 2008. Revised 2013. Accessed December 13, 2013.
30. 2013 ISCD Offical Positions - Adult The International Society for Clinical Densitometry website [Updated August 15, 2013. Accessed December 13, 2013]. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult.
31. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton L.J., Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008, 42:467-475.
32. Miller P.D., Schwartz E.N., Chen P., Misurski D.A., Krege J.H. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007, 18:59-68.
33. Dawson-Hughes B., Chen P., Krege J.H. Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 2007, 92:4630-4636.
34. Uusi-Rasi K., Semanick L.M., Zanchetta J.R., Bogado C.E., Eriksen E.F., Sato M., et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
35. Minne H., Audran M., Simoes M.E., Obermayer-Pietsch B., Sigursson G., Marin F., et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008, 24:3117-3128.
36. Obermayer-Pietsch B.M., Marin F., McCloskey E.V., Hadji P., Farrerons J., Boonen S., et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008, 23:1591-1600.
37. Ettinger B., San M.J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
38. Gonnelli S., Martini G., Caffarelli C., Salvadori S., Cadirni A., Montagnani A., et al. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis. Osteoporos Int 2006, 17:1524-1531.
39. Cosman F., Wermers R.A., Recknor C., Mauck K.F., Xie L., Glass E.V., et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009, 94:3772-3780.
40. Deal C., Omizo M., Schwartz E.N., Eriksen E.F., Cantor P., Wang J., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005, 20:1905-1911.
41. Cosman F., Eriksen E.F., Recknor C., Miller P.D., Guanabens N., Kasperk C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
42. Walker M.D., Cusano N.E., Sliney J., Romano M., Zhang C., McMahon D.J., et al. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 2013, 44:237-246.
43. Tsai J.N., Uihlein A.V., Lee H., Kumbhani R., Siwila-Sackman E., McKay E.A., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013, 382:50-56.
44. Leder B.Z., Tsai J.N., Uihlein A.V., Burnett-Bowie S.A., Zhu Y., Foley K., et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J Clin Endocrinol Metab 2014, 99:1694-1700.
45. Muschitz C., Kocijan R., Fahrleitner-Pammer A., Lung S., Resch H. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 2013, 28:196-205.
46. Heaney R.P., Recker R.R., Watson P., Lappe J.M. Phosphate and carbonate salts of calcium support robust bone building in osteoporosis. Am J Clin Nutr 2010, 92:101-105.
47. Prince R., Sipos A., Hossain A., Syversen U., Ish-Shalom S., Marcinowska E., et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005, 20:1507-1513.
48. Adami S., San M.J., Munoz-Torres M., Econs M.J., Xie L., Dalsky G.P., et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008, 19:87-94.
49. Eastell R., Nickelsen T., Marin F., Barker C., Hadji P., Farrerons J., et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009, 24:726-736.
50. Kaufman J.M., Johnell O., Abadie E., Adami S., Audran M., Avouac B., et al. Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 2000, 59:765-772.
51. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., ez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
52. Kaufman J.M., Orwoll E., Goemaere S., San M.J., Hossain A., Dalsky G.P., et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
53. Civitelli R., Ziambaras K. Epidemiology of glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008, 31:2-6.
54. Saag K.G., Zanchetta J.R., Devogelaer J.P., Adler R.A., Eastell R., See K., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60:3346-3355.
55. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
56. Devogelaer J.P., Adler R.A., Recknor C., See K., Warner M.R., Wong M., et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 2010, 37:141-148.
57. Losada B.R., Zanchetta J.R., Zerbini C., Molina J.F., De la P.P., Liu C.C., et al. Active comparator trial of teriparatide vs. alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. J Clin Densitom 2009, 12:63-70.
58. Gluer C.C., Marin F., Ringe J.D., Hawkins F., Moricke R., Papaioannu N., et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013, 28:1355-1368.
59. Koski A.M., Loyttyniemi E., Vaananen H., Laine H., Niskanen L., Nevalainen P.I., et al. The effectiveness of teriparatide in the clinical practice-attenuation of the bone mineral density outcome by increasing age and bisphosphonate pretreatment. Ann Med 2013, 45:230-235.
60. Middleton E.T., Steel S.A., Doherty S.M. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int 2007, 81:335-340.
61. Stroup J.S., Rivers S.M., Abu-Baker A.M., Kane M.P. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Pharmacotherapy 2007, 27:779-788.
62. Keel C., Kraenzlin M.E., Kraenzlin C.A., Muller B., Meier C. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab 2010, 28:68-76.
63. Unnanuntana A., Ton Q.V., Kleimeyer J.P., Nguyen J.T., Lane J.M. A fracture does not adversely affect bone mineral density responses after teriparatide treatment. Clin Orthop Relat Res 2012, 470:927-936.
64. Horowitz B.S., Horowitz M.E., Fonseca S., Ruiz M., Kaye W.A. An 18-month open-label trial of teriparatide in patients with previous parathyroidectomy at continued risk for osteoporotic fractures: an exploratory study. Endocr Pract 2011, 17:377-383.
65. Michalska D., Luchavova M., Zikan V., Raska I., Kubena A.A., Stepan J.J. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Osteoporos Int 2012, 23:2885-2891.
66. Creatsa M., Pliatsika P., Kaparos G., Antoniou A., Armeni E., Tsakonas E., et al. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study. J Obstet Gynaecol Res 2011, 37:1415-1422.
67. Hwang J.S., Tu S.T., Yang T.S., Chen J.F., Wang C.J., Tsai K.S. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006, 17:373-378.
68. Kung A.W., Pasion E.G., Sofiyan M., Lau E.M., Tay B.K., Lam K.S., et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 2006, 22:929-937.
69. Miyauchi A., Matsumoto T., Shigeta H., Tsujimoto M., Thiebaud D., Nakamura T. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab 2008, 26:624-634.
70. Miyauchi A., Matsumoto T., Sugimoto T., Tsujimoto M., Warner M.R., Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010, 47:493-502.
71. Sethi B.K., Chadha M., Modi K.D., Kumar K.M., Mehrotra R., Sriram U. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis-an Indian experience. J Assoc Physicians India 2008, 56:418-424.
72. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., Gordon D.N., Papapoulos S., Bone H.G., et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011, 96:2441-2449.
73. Heaney R.P., Watson P. Variability in the measured response of bone to teriparatide. Osteoporos Int 2011, 22:1703-1708.
74. Chen P., Miller P.D., Recker R., Resch H., Rana A., Pavo I., et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007, 22:1173-1180.
75. Keaveny T.M., McClung M.R., Wan X., Kopperdahl D.L., Mitlak B.H., Krohn K. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 2012, 50:165-170.
76. Cody D.D., Gross G.J., Hou F.J., Spencer H.J., Goldstein S.A., Fyhrie D.P. Femoral strength is better predicted by finite element models than QCT and DXA. J Biomech 1999, 32:1013-1020.
77. Crawford R.P., Cann C.E., Keaveny T.M. Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone 2003, 33:744-750.
78. Keaveny T.M. Biomechanical computed tomography-noninvasive bone strength analysis using clinical CT scans. Ann N Y Acad Sci 2010, 1192:57-65.
79. Bessho M., Ohnishi I., Matsuyama J., Matsumoto T., Imai K., Nakamura K. Prediction of strength and strain of the proximal femur by a CT-based finite element method. J Biomech 2007, 40:1745-1753.
80. Buckley J.M., Loo K., Motherway J. Comparison of quantitative computed tomography-based measures in predicting vertebral compressive strength. Bone 2007, 40:767-774.
81. Imai K., Ohnishi I., Bessho M., Nakamura K. Nonlinear finite element model predicts vertebral bone strength and fracture site. Spine (Phila Pa 1976) 2006, 31:1789-1794.
82. Keyak J.H., Falkinstein Y. Comparison of in situ and in vitro CT scan-based finite element model predictions of proximal femoral fracture load. Med Eng Phys 2003, 25:781-787.
83. Lengsfeld M., Schmitt J., Alter P., Kaminsky J., Leppek R. Comparison of geometry-based and CT voxel-based finite element modelling and experimental validation. Med Eng Phys 1998, 20:515-522.
84. Martin H., Werner J., Andresen R., Schober H.C., Schmitz K.P. Noninvasive assessment of stiffness and failure load of human vertebrae from CT-data. Biomed Tech (Berl) 1998, 43:82-88.
85. Wang X., Sanyal A., Cawthon P.M., Palermo L., Jekir M., Christensen J., et al. Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res 2012, 27:808-816.
86. Borggrefe J., Graeff C., Nickelsen T.N., Marin F., Gluer C.C. Quantitative computed tomographic assessment of the effects of 24months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 2010, 25:472-481.
87. Poole K.E., Treece G.M., Ridgway G.R., Mayhew P.M., Borggrefe J., Gee A.H. Targeted regeneration of bone in the osteoporotic human femur. PLoS One 2011, 6:e16190.
88. Cosman F., Keaveny T.M., Kopperdahl D., Wermers R.A., Wan X., Krohn K.D., et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 2013, 28:1328-1336.
89. Krege J.H., Wan X. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone 2012, 50:161-164.
90. Boonen S., Marin F., Mellstrom D., Xie L., Desaiah D., Krege J.H., et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006, 54:782-789.
91. Delmas P.D., Licata A.A., Reginster J.Y., Crans G.G., Chen P., Misurski D.A., et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006, 39:237-243.
92. Silverman S., Miller P., Sebba A., Weitz M., Wan X., Alam J., et al. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int 2013, 24:2309-2317.
93. Langdahl B.L., Rajzbaum G., Jakob F., Karras D., Ljunggren O., Lems W.F., et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009, 85:484-493.
94. Rajzbaum G., Jakob F., Karras D., Ljunggren O., Lems W.F., Langdahl B.L., et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008, 24:377-384.
95. Walsh J.B., Lems W.F., Karras D., Langdahl B.L., Ljunggren O., Fahrleitner-Pammer A., et al. Effectiveness of teriparatide in women over 75years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2012, 90:373-383.
96. Jakob F., Oertel H., Langdahl B., Ljunggren O., Barrett A., Karras D., et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 2012, 166:87-97.
97. Lindsay R., Miller P., Pohl G., Glass E.V., Chen P., Krege J.H. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2009, 20:943-948.
98. Benhamou C.L. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007, 74:39-47.
99. Blake G.M., Frost M.L., Moore A.E., Siddique M., Fogelman I. The assessment of regional skeletal metabolism: studies of osteoporosis treatments using quantitative radionuclide imaging. J Clin Densitom 2011, 14:263-271.
100. Han S.L., Wan S.L. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract 2012, 66:199-209.
101. Lau A.N., Adachi J.D. Role of teriparatide in treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag 2010, 6:497-503.
102. Quattrocchi E., Kourlas H. Teriparatide: a review. Clin Ther 2004, 26:841-854.
103. Stroup J., Kane M.P., Abu-Baker A.M. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 2008, 65:532-539.